Related Experiment Videos
The HPV DNA virus hybrid capture assay: what is it--and where do we go from here?
John P Vernick1, Carmen K Steigman
1Wayne State University School of Medicine, Cytopathology Department, Detroit Medical Center, Wayne State University, Detroit, USA.
Abstract:
The biotechnology that has made HPV DNA testing possible has the capacity to reduce the incidence of cervical carcinoma substantially, especially in the patients diagnosed with ambiguous low-grade lesions, such as ASC-US, on Pap smears. Reflex HPV DNA testing of thin layer preparations diagnosed as ASC-US, and in other certain instances as outlined by ASCCP, will play a major role in the management of abnormal cervical cytology. Other applications, such as possible primary screening, may in the future play a substantial role in cervical screening. These potential applications will require more in-depth study and research, and will ultimately have to stand the test of time.